Travere director trades 4,500 shares via option exercise
Travere Therapeutics director Roy D. Baynes exercised stock options and sold the resulting shares in a pre-planned transaction.
Rhea-AI Filing Summary
Travere Therapeutics director Roy D. Baynes exercised stock options and sold the resulting shares in a pre-planned transaction. On May 5, he exercised options for 4,500 shares of common stock at $18.27 per share and sold 4,500 shares at $46.65 per share in an open-market sale. The sale was made under a written Rule 10b5-1(c) trading plan adopted on November 17, 2025 and involved fully vested, exercisable options. After these transactions, Baynes directly owns 37,500 shares of Travere Therapeutics common stock, with no remaining position from the exercised options.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 4,500 shares ($128K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Baynes Roy D.
Role
Director
Sold
4,500 shs ($210K)
Approx. gross sale proceeds
$210K
Approx. exercise cost
$82K
Approx. pre-tax spread
$128K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 4,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 4,500 | $18.27 | $82K |
| Sale | Common Stock | 4,500 | $46.65 | $210K |
Holdings After Transaction:
Stock option (right to buy) — 0 contracts (Direct);
Common Stock — 37,500 shares (Direct)
Footnotes (2)
- F1. This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.
- F2. The stock option is fully vested and exercisable.
Key Figures
Shares sold: 4,500 shares
Sale price: $46.65 per share
Options exercised: 4,500 shares
+3 more
6 metrics
Shares sold
4,500 shares
Open-market sale of common stock on May 5, 2026 at $46.65
Sale price
$46.65 per share
Price for 4,500 common shares sold on May 5, 2026
Options exercised
4,500 shares
Stock options converted into common stock on May 5, 2026
Exercise price
$18.27 per share
Exercise price of stock option covering 4,500 shares
Shares owned after
37,500 shares
Direct Travere Therapeutics common stock holdings after transactions
Option expiration
May 14, 2031
Expiration date originally stated for the exercised stock option
Key Terms
Rule 10b5-1(c), stock option, open-market sale
3 terms
Rule 10b5-1(c) regulatory
"written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
stock option financial
"consists of the sale of shares underlying stock options granted to the Reporting Person"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
open-market sale financial
"transaction_action is described as an open-market sale of common stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Travere Therapeutics (TVTX) director Roy D. Baynes report in this Form 4?
Roy D. Baynes reported exercising stock options for 4,500 Travere Therapeutics shares and selling 4,500 common shares. The transactions occurred on May 5 as an open-market sale tied to fully vested options, and he remains a direct shareholder after the trades.
At what price did Roy D. Baynes exercise his Travere Therapeutics (TVTX) stock options?
Baynes exercised stock options covering 4,500 Travere Therapeutics shares at an exercise price of $18.27 per share. The options were fully vested and exercisable, meaning he had already earned them before converting them into common shares.
What happened to Roy D. Baynes’ Travere Therapeutics (TVTX) stock options in this filing?
He exercised a stock option for 4,500 underlying Travere Therapeutics shares, which was fully vested and exercisable. After exercising and selling the resulting common shares, the filing shows that stock option holding at zero, indicating the entire option grant was used.
AI-generated analysis. How Rhea-AI works. Not financial advice.
